Information Library
Results for: Phase II/III - Emerging Biopharma
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
Partnering is Key to Maximizing Rewards in Emerging Markets
Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.
-
Emerging Biopharma Service Fact Sheet
Brochure — May 4, 2010
Recognizing that the needs of emerging companies are unique, Quintiles has created a specialized team dedicated exclusively to small and mid-sized biopharma companies. -
PharmAsia News Article Reprint
Media Coverage — March 1, 2010
Quintiles Asia Executives Say CROs Must Evaluate, Adjust To New Health Landscape: An Interview With PharmAsia News. -
BIOS Standardize Data with SPARC
Brochure — February 2, 2010
There is an increasing global requirement for Clinical Data Interchange Standards Consortium (CDISC) -based standardized data for regulatory submissions. At Quintiles, we have proactively addressed this need by training our staff, gaining experience, and developing and implementing innovative solutions for creating data that adhere to current CDISC Study Data Tabulation Model (SDTM) specifications. -
Enabling Transformation
Case Study — September 30, 2009
Biovitrum found an ideal opportunity to transform itself into a fully integrated specialty pharmaceutical company from a biotech discovery and early clinical development company.
Page 1 of 1 (5 results)
